Related Experiment Video
Updated: Dec 28, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Androgen receptor-binding sites are highly mutated in prostate cancer
Tunç Morova1,2, Daniel R McNeill3, Nada Lallous2
1School of Medicine, Koç University, Istanbul, 34450, Turkey.
Abstract:
Androgen receptor (AR) signalling is essential in nearly all prostate cancers. Any alterations to AR-mediated transcription can have a profound effect on carcinogenesis and tumor growth. While mutations of the AR protein have been extensively studied, little is known about those somatic mutations that occur at the non-coding regions where AR binds DNA. Using clinical whole genome sequencing, we show that AR binding sites have a dramatically increased rate of mutations that is greater than any other transcription factor and specific to only prostate cancer. Demonstrating this may be common to lineage-specific transcription factors, estrogen receptor binding sites were also found to have elevated rate of mutations in breast cancer. We provide evidence that these mutations at AR binding sites, and likely other related transcription factors, are caused by faulty repair of abasic sites. Overall, this work demonstrates that non-coding AR binding sites are frequently mutated in prostate cancer and can impact enhancer activity.
Insights
Prostate cancer frequently mutates androgen receptor (AR) binding sites in non-coding DNA, unlike other transcription factors. These mutations, possibly from faulty DNA repair, can affect tumor growth and enhancer activity.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Androgen receptor (AR) signaling is crucial for most prostate cancers.
- While AR protein mutations are studied, non-coding AR DNA binding site mutations are less understood.
Purpose of the Study:
- To investigate somatic mutations at AR binding sites in prostate cancer.
- To determine if these mutations are specific to prostate cancer and AR, and to identify potential causes.
Main Methods:
- Analysis of clinical whole genome sequencing data.
- Comparison of mutation rates at AR binding sites with other transcription factor binding sites.
- Investigation of estrogen receptor binding sites in breast cancer for comparison.
Main Results:
- AR binding sites show a significantly elevated mutation rate, exceeding other transcription factors and specific to prostate cancer.
- Estrogen receptor binding sites also exhibit increased mutations in breast cancer, suggesting a lineage-specific pattern.
- Evidence suggests faulty repair of abasic sites as the cause of these non-coding mutations.
Conclusions:
- Non-coding AR binding sites are frequently mutated in prostate cancer.
- These mutations can influence enhancer activity and potentially impact carcinogenesis and tumor progression.
- The findings highlight the importance of non-coding DNA mutations in cancer development.
Related Concept Videos
Abnormal Proliferation
Conserved Binding Sites
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
Intracellular Hormone Receptors
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Mitogens and the Cell Cycle
Ligand Binding and Linkage

